【24h】

Pregnane X receptor activation potentiates ritonavir hepatotoxicity

机译:孕烷X受体激活增强利托那韦肝毒性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Ritonavir (RTV) is on the World Health Organization's list of essential medicines for antiretroviral therapy, but can cause hepatotoxicity by unknown mechanisms. Multiple clinical studies found that hepatotoxicity occurred in 100 of participants who were pretreated with rifampicin or efavirenz followed by RTV-containing regimens. Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with marked interspecies differences in ligand-dependent activation. Using PXR-humanized mouse models, we recapitulated the RTV hepatotoxicity observed in the clinic. PXR was found to modulate RTV hepatotoxicity through CYP3A4-dependent pathways involved in RTV bioactivation, oxidative stress, and endoplasmic reticulum stress. In summary, the current work demonstrated the essential roles of human PXR and CYP3A4 in RTV hepatotoxicity, which can be applied to guide the safe use of RTV-containing regimens in the clinic.
机译:利托那韦(RTV)是世界卫生组织抗逆转录病毒治疗的基本药物清单,但可通过未知机制引起肝毒性。多项临床研究发现,在接受利福平或依非韦仑预处理后接受含 RTV 方案的受试者中,100% 发生肝毒性。利福平和依非韦伦都是孕烷 X 受体 (PXR) 的激活剂,PXR 是一种转录因子,在配体依赖性激活方面具有显着的种间差异。使用PXR人源化小鼠模型,我们概括了在临床上观察到的RTV肝毒性。发现 PXR 通过参与 RTV 生物活化、氧化应激和内质网应激的 CYP3A4 依赖性途径调节 RTV 肝毒性。综上所述,目前的工作证明了人PXR和CYP3A4在RTV肝毒性中的重要作用,可用于指导临床中含RTV方案的安全使用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号